Research programme: antibacterial therapeutics- Da Volterra

Drug Profile

Research programme: antibacterial therapeutics- Da Volterra

Alternative Names: DAV-121; DAV-210

Latest Information Update: 25 Jan 2016

Price : $50

At a glance

  • Originator Da Volterra
  • Class Anti-infectives; Antibacterials
  • Mechanism of Action Bacteria replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Intestinal infections; Urinary tract infections

Most Recent Events

  • 31 Dec 2015 Preclinical trials in Intestinal infections in France before December 2015 (PO)
  • 31 Dec 2015 Preclinical trials in Urinary tract infections in France before December 2015 (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top